Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Robin Kate Kelley et al.|New England Journal of Medicine|2023Cited by 530
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoDaniel Cejka, Volker Wacheck|British Journal of Cancer|2009Cited by 39
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancerDaisuke Sakai, Toshihiko Doi, Hyun Cheol Chung et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 31
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsVolker Wacheck, Richard F. Schlenk|Cancer Management and Research|2011Cited by 5